Sort   by:  
 Page size 
UnknownTargeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
Not available
S-EPMC6409688 | biostudies-literature
UnknownIdentification of DUSP4/6 overexpression as a potential rheostat to NRAS-induced hepatocarcinogenesis.
Not available
S-EPMC10636894 | biostudies-literature
UnknownOncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.
Not available
S-EPMC5384589 | biostudies-literature
UnknowneIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma.
Not available
S-EPMC9917075 | biostudies-literature
UnknownFatty Acid Synthase Promotes Hepatocellular Carcinoma Growth via S-Phase Kinase-Associated Protein 2/p27KIP1 Regulation.
Not available
S-EPMC11278665 | biostudies-literature
UnknownInactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.
Not available
S-EPMC4718802 | biostudies-literature
UnknownOverexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma.
Not available
S-EPMC11193761 | biostudies-literature
UnknownHSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma.
Not available
S-EPMC11378393 | biostudies-literature
UnknownDeregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis.
Not available
S-EPMC5710874 | biostudies-literature
UnknownPan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
Not available
S-EPMC5696057 | biostudies-literature
Sort   by:  
 Page size